Findings from University of Washington Yields New Data on Managed Care (Use of Real-world Evidence In Economic Assessments of Pharmaceuticals In the United States)

2021 FEB 23 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Managed Care is the subject of a report. According to news reporting from Seattle, Washington, by NewsRx journalists, research stated, “Despite the increasing interest in expanding the use of real-world evidence (RWE) in economic assessments of pharmaceuticals, decision makers face uncertainty about how RWE should be used. To assess the use of RWE in economic assessments of drugs by the Institute for Clinical and Economic Review (ICER).”

Financial supporters for this research include University of Washington School of Pharmacy Corporate Advisory Board Health Tech Fund (HTF), Institute for Clinical and Economic Review.

The news correspondents obtained a quote from the research from the University of Washington, “We reviewed cost-effectiveness and budget impact analyses in final evidence reports of pharmaceuticals published by ICER. We calculated the total number of RWE uses and the proportion of model inputs informed by RWE per report. We classified model inputs into 15 categories based on their attributes and then examined what category each RWE informed to classify the reason for RWE use. Finally, we characterized RWE by study design, data source, and sponsor type. We identified 33 reports, all of which used RWE; the mean RWE use per report was 12 (range .4-26). The average proportion of model inputs informed by RWE per report was 32.7%, but this proportion had a wide range (range=4.1%-76.9%). RWE was most commonly used for disease progression inputs (28.7%) and health care resource utilization and costs (21.1%), but was rarely used for drug-specific clinical outcomes such as effectiveness (1.5%), adverse drug event rates (0.5%), and discontinuation rates (1.2%). The most frequently used study design was a retrospective cohort (56.6%), and the most frequently used data source was registry data (41.4%). About a third (30.2%) of RWE was industry-sponsored. RWE has been commonly used to inform pharmaceutical value assessments conducted by ICER.”

According to the news reporters, the research concluded: “However, there has been relatively limited use of RWE to inform drug-specific effectiveness, despite calls for greater inclusion of RWE in value assessments for real-world drug effectiveness.”

This research has been peer-reviewed.

For more information on this research see: Use of Real-world Evidence In Economic Assessments of Pharmaceuticals In the United States. Journal of Managed Care & Specialty Pharmacy, 2021;27(1):5-14. Journal of Managed Care & Specialty Pharmacy can be contacted at: Academy of Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

Our news journalists report that additional information may be obtained by contacting David L. Veenstra, University of Washington, School of Pharmacy, Choice Inst, Seattle, WA 98195, United States. Additional authors for this research include Woojung Lee, Victoria Dayer, Boshen Jiao, Josh J. Carlson and Beth Devine.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.18553/jmcp.2021.27.1.005. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)